Zoetis/$ZTS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Zoetis
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Ticker
$ZTS
Sector
Primary listing
NYSE
Industry
Pharmaceuticals
Headquarters
Employees
13,800
ISIN
US98978V1035
Website
Zoetis Metrics
BasicAdvanced
$66B
26.68
$5.57
0.94
$1.86
1.35%
Price and volume
Market cap
$66B
Beta
0.94
52-week high
$194.42
52-week low
$139.70
Average daily volume
3M
Dividend rate
$1.86
Financial strength
Current ratio
1.736
Quick ratio
0.916
Long term debt to equity
116.455
Total debt to equity
145.628
Dividend payout ratio (TTM)
32.25%
Interest coverage (TTM)
15.56%
Profitability
EBITDA (TTM)
3,867
Gross margin (TTM)
70.96%
Net profit margin (TTM)
27.12%
Operating margin (TTM)
37.02%
Effective tax rate (TTM)
20.90%
Revenue per employee (TTM)
$670,000
Management effectiveness
Return on assets (TTM)
15.11%
Return on equity (TTM)
52.09%
Valuation
Price to earnings (TTM)
26.676
Price to revenue (TTM)
7.227
Price to book
14.24
Price to tangible book (TTM)
77.34
Price to free cash flow (TTM)
29.42
Free cash flow yield (TTM)
3.40%
Free cash flow per share (TTM)
505.09%
Dividend yield (TTM)
1.25%
Forward dividend yield
1.35%
Growth
Revenue change (TTM)
6.32%
Earnings per share change (TTM)
7.32%
3-year revenue growth (CAGR)
5.58%
10-year revenue growth (CAGR)
6.84%
3-year earnings per share growth (CAGR)
8.52%
10-year earnings per share growth (CAGR)
16.79%
3-year dividend per share growth (CAGR)
18.66%
10-year dividend per share growth (CAGR)
19.64%
What the Analysts think about Zoetis
Analyst ratings (Buy, Hold, Sell) for Zoetis stock.
Bulls say / Bears say
Zoetis raised its 2024 profit and revenue forecasts, anticipating adjusted earnings per share between $5.78 and $5.88, driven by strong demand for pet medicines and vaccines. (reuters.com)
BTIG initiated coverage on Zoetis with a 'Buy' rating and a $220 price target, citing the company's robust product portfolio and growth in the animal health market. (investing.com)
Stifel raised its price target for Zoetis to $200, highlighting the company's strong market position and potential for continued growth in the parasiticide segment. (investing.com)
Zoetis' stock reached a 52-week low of $144.53 amid market shifts, reflecting investor concerns over potential challenges in the animal health sector. (investing.com)
The company forecasted 2025 profit and revenue below Wall Street estimates, partly due to a stronger dollar, leading to a 9% drop in shares during premarket trading. (reuters.com)
Zoetis' stock has declined by 11.47% over the past year, indicating potential investor concerns about the company's growth prospects and market conditions. (investing.com)
Data summarised monthly by Lightyear AI. Last updated on 27 Jun 2025.
Zoetis Financial Performance
Revenues and expenses
Zoetis Earnings Performance
Company profitability
Zoetis News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Sept3
Zoetis
Dividend·Payment
$0.50Per share
FAQs
What’s the current market cap for Zoetis stock?
Zoetis (ZTS) has a market cap of $66B as of July 21, 2025.
What is the P/E ratio for Zoetis stock?
The price to earnings (P/E) ratio for Zoetis (ZTS) stock is 26.68 as of July 21, 2025.
Does Zoetis stock pay dividends?
Yes, the Zoetis (ZTS) stock pays dividends to shareholders. As of July 21, 2025, the dividend rate is $1.864 and the yield is 1.35%. Zoetis has a payout ratio of 32.25% on a trailing twelve-month basis.
When is the next Zoetis dividend payment date?
The next Zoetis (ZTS) dividend payment is scheduled for September 03, 2025.
What is the beta indicator for Zoetis?
Zoetis (ZTS) has a beta rating of 0.94. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.